
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 29, 2013

InfuSystem Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-35020
(Commission
File Number)

20-3341405
(I.R.S. Employer
Identification No.)

31700 Research Park Drive
Madison Heights, Michigan 48071
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (248) 291-1210

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. Regulation FD.

InfuSystem Holdings, Inc. (the “Company”) hereby furnishes the information in Exhibit 99.1 hereto, the investor presentation dated August 29, 2013. The Company intends to deliver this presentation following the conclusion of its 2013 Annual Meeting of Stockholders.

Item 9.01. Financial Statements and Exhibits**(d) Exhibits**

99.1 InfuSystem Holdings, Inc. Investor Presentation dated August 29, 2013.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFUSYSTEM HOLDINGS, INC.

By: /s/ Jonathan P. Foster

Name: Jonathan P. Foster

Title: Chief Financial Officer

Dated: August 29, 2013

EXHIBIT INDEX

Exhibit 99.1 InfuSystem Holdings, Inc. Investor Presentation dated August 29, 2013.

InfuSystem Holdings, Inc.

Post Shareholders Meeting

August 29, 2013

Eric K. Steen, CEO

Jonathan P. Foster, CFO



Safe Harbor Statement

Certain statements contained in this release are forward-looking statements and are based on future expectations, plans and prospects for InfuSystem Holdings, Inc.'s ("InfuSystem", "INFU", "the Company", "We") business and operations that involve a number of risks and uncertainties. InfuSystem's outlook for 2013 and other forward-looking statements in this release are made as of August 29, 2013, and the Company disclaims any duty to supplement, update or revise such statements on a going-forward basis, whether as a result of subsequent developments, changed expectations or otherwise. In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, potential changes in overall healthcare reimbursement – including CMS competitive bidding, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, US Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, dependency on websites and intellectual property, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and covenants, and other risks associated with our common stock, as well as any other litigation to which the Company may be subject from time to time; and other risk factors as discussed in the Company's annual report on Form 10-K for the year ended December 31, 2012 and in other filings made by the Company from time to time with the Securities and Exchange Commission.



Positioned for Growth



Positioned For Growth

Market Trends

- InfuSystem is uniquely positioned to take advantage of market trends

Strategy

- Transformational strategy is developed and being implemented

Leadership

- Leadership can now focus on running a business for first time in over a year



InfuSystem Patient Population is Extension of Infusion Therapy From Clinic to Home

Discharge
Planner

HIT
HHA
DME
IHSCH

Home
Infusion
InfuSystem



InfuSystem
INFUSION MADE EASY.™

Extension of Clinic to Home



Ambulatory Infusion

- Some drugs more effective when infused continuously
- Patient Satisfaction
- Multiple Therapies - Oncology, Post Surgical Pain, Special Disease States

Payor Contracts

- Over 250 Payor Contracts
- Private Pay & Government
- Commercial Payors reimburse more therapies than CMS



Population Growth, Age and Growth of Cancers

Population Stats

- Aging Population
- At-risk lifestyles persist (red, processed meats).

Colo-rectal


- 3rd most common in US and Worldwide



U.S. Population

3 1 6 , 5 1 8 , 8 0 4

Infu Oncology Patients




CR Contrib. Factors*

- Are older than 60
- Eat a lot of red or processed meats
- Have colo-rectal polyps
- Have a family history of colon cancer
- Have a personal history of breast cancer
- Smoking and Alcohol

* A.D.A.M. Medical Encyclopedia




InfuSystem Cancer Patients



Revenue Diversity

2009 Revenues




■ Rentals - Colorectal Cancer
■ Rentals - Pain Management
■ Sales - DP

■ Rentals - Other Cancers
■ Rentals - Hospitals/Home Care


■ Rentals - Infectious Disease
■ Rentals - Service & Repair

Revenue Diversity

2009 Revenues



2012 Revenues




- Rentals - Colorectal Cancer
- Rentals - Pain Management
- Sales - DP

- Rentals - Other Cancers
- Rentals - Hospitals/Home Care

- Rentals - Infectious Disease
- Rentals - Service & Repair

Increasing Therapy Offerings to Payors



Continuous Peripheral Nerve Block at Home

- There are 5.69M orthopedic surgeries annual.
- ~50% of these patients are potential candidates for pain management with a continuous peripheral nerve block (CPNB) Growth of CPNB
- Growth of CPNB at Home
- HCAHPS (H CAPS): Pain Scores affect Hospital Reimbursement.



Total Home Infusion Market

\$9B -
\$11B

Home Infusion Market

Home Infusion

- Lower cost than clinical setting
- Increasing Importance to lower cost in Affordable Care Act future
- Lowest cost and highest patient satisfaction site for extension of infusion therapy is the home

InfuSystem Niche

- Therapy started in a clinic
- Estimated over \$600 Million market. InfuSystem has 10 % of total and leading share of Oncology with 1,600 practice sites served.



Biomedical Rentals, Service and Repair



Pump Rentals, Asset Management and Sales

- Direct Sales of Device and Supplies
- Pump Broker – ability to acquire CAP EX in cost effective way
- Asset Management, Rental and Lease

Preventative Maint.


- Annual Pump Recertification
- Preventative Maintenance
- Warranty

Repair

- ISO Certified Service Facilities – Recertification just passed !
- Regional Distribution
- 28 Certified Technicians




Offering Infusion to All Points of Care



InfuSystem
INFUSION MADE EASY.™

Full Line Multi-Therapy & Multi-Point Offering



Device & Pharma Manufacturer,
Distributor, GPO, ACO



What a Difference a Year Makes

- Financial Position
- New Team in place
- IT improvements begun
- New Product launches – Kits, Smart Pumps, Post Surgical Pain



IT and Automation



Shift into High Gear

- More insurance billings with existing staff
- Greater revenue per employee
- Road Map completed ,
New iPad features,
Automation of initial
internal processes

InfuSystem
INFUSION MADE EASY.™

Connectivity through eMAR , Web Portal and System Interface



Bring the Pumps to the People in Large Markets



Largest Markets

- #1 New York
- #2 Los Angeles
- #3 Houston + Dallas
- #4 Atlanta + Miami
- #5 Chicago

InfuSystem
INFUSION MADE EASY.™

For Faster Turnaround and Improved Utilization



InfuSystem Distribution

- New Houston Service Center
- Expanded Los Angeles Area Service Center
- High-density Metro Markets
- Large Customers



Where Does This Get INFU in Three Years ?

- Aging Population and Cancer growth
- More Patients Home IV , commercial pay recognizing value, CMS competitive bidding
- Peripheral Nerve Block and Smart Pump Growth
- Revenue Growth in High Single Digits



Next Up - Action Items

- IT Implementation – web portal, eMar, interfaces, automation of insurance processes
- Product and service line expansion
- Geographic Expansion
- Productivity measures implemented
 - Evaluating depreciable life
- Utilization metrics and improvement



Positioned For Growth

Market Trends

- InfuSystem is uniquely positioned to take advantage of market trends

Strategy

- Transformational strategy is developed and being implemented

Leadership

- Leadership can now focus on running a business for first time in over a year



Financial Review



Ambulatory Rental Pump Fleet

- With over 26,000+ pumps in TPP Rental Fleet, InfuSystem maintains the largest fleet of ambulatory infusion pumps in the industry
- DPP Rental Fleet has over 20,000 pumps
- The Company has a complete inventory of virtually every model pump from every leading manufacturer, allowing InfuSystem to provide the right pump for any patient's prescribed protocol
- Purchases of pumps have a high return on investment and an useful life of 10-15 years

TPP Ambulatory Pump Financial Profile

Average Cost	~\$1,500/pump
Average Monthly Revenue	~\$300/pump
Treatment Duration	4 – 6 months
Useful Life	10-15 years
Lifetime Revenue/Pump	Approx. ~\$20,000+

Annual Rental Revenue per \$1 Rental Fleet Cost ("Revenue Ratio")

All Rentals (Both DP and TPP) -

	YE 2011	YE 2012	Q1 2013	Q2 2013
Rental Revenue (\$K)	\$ 46,795	\$ 53,471	\$ 13,445	\$ 13,618
Medical Equipment in Service - Cost (\$K)	\$ 31,734	\$ 34,193	\$ 35,026	\$ 35,474
Rental Revenue Per Dollar of Medical Equipment in Service Invested – Annualized	\$ 1.47	\$ 1.56	\$ 1.54	\$ 1.54



Competitive Bidding Overview

Competitive Bidding Overview

- InfuSystem was not involved in Round 1 nor Round 2 of Competitive Bidding
- CMS announced a Recompete of Round 1 competitive bidding on April 17th
 - External infusion pumps/supplies added as a new product category
 - A supplier must bid on all items within the product category to have its RFP considered
 - Recompete covers 9 Metropolitan Statistical Areas (MSAs)

InfuSystem's Response to Competitive Bidding

- InfuSystem has engaged consultants and industry professionals to discuss directly with CMS, advise on positioning the Company for potential regulatory changes, and facilitate potential strategic partnership opportunities
- Competitive environment will vary in accordance with the level of cuts by CMS

CMS Competitive Bidding "Target" Timetable as of August 20, 2012



* These dates are subject to change

CMS will institute some form of competitive bidding nationwide by January 2016.




Summary Income Statement

(\$000's)	FY2009	FY2010	FY2011	FY2012	6 Mo 2012	6 Mo 2013
Net revenues:						
Rentals			\$ 46,795	\$ 53,471	\$ 25,878	\$ 27,061
Product sales			\$ 7,842	\$ 5,357	\$ 2,542	\$ 2,302
Net revenues	\$ 38,964	\$ 47,229	\$ 54,637	\$ 58,828	\$ 28,420	\$ 29,363
Cost of revenues:						
Product, service and supply costs	\$ 6,200	\$ 7,730	\$ 9,128	\$ 9,165	\$ 4,383	\$ 5,424
Pump depreciation and loss on disposal	\$ 4,127	\$ 5,954	\$ 10,154	\$ 6,752	\$ 3,327	\$ 3,186
Gross profit			\$ 35,355	\$ 42,911	\$ 20,710	\$ 20,753
Provision for doubtful accounts	\$ 4,006	\$ 4,515	\$ 4,099	\$ 5,251	\$ 2,140	\$ 2,987
Amortization of intangibles	\$ 1,827	\$ 2,259	\$ 2,662	\$ 2,734	\$ 1,358	\$ 1,324
Asset impairment charges			\$ 67,592			
Selling and marketing	\$ 5,258	\$ 7,087	\$ 9,371	\$ 9,864	\$ 5,286	\$ 4,890
General and administrative	\$ 12,218	\$ 20,622	\$ 17,987	\$ 23,062	\$ 12,410	\$ 10,039
Operating income (loss)	\$ 5,328	\$ (938)	\$ (66,356)	\$ 2,000	\$ (484)	\$ 1,513
Total other (loss)	\$ (3,577)	\$ (2,285)	\$ (2,221)	\$ (4,152)	\$ (1,814)	\$ (1,462)
Loss before income taxes	\$ 1,751	\$ (3,223)	\$ (68,577)	\$ (2,152)	\$ (2,298)	\$ 51
Income tax benefit	\$ (977)	\$ 1,371	\$ 23,134	\$ 663	\$ 555	\$ 105
Net income (loss)	\$ 774	\$ (1,852)	\$ (45,443)	\$ (1,489)	\$ (1,743)	\$ 156
EBITDA	\$ 11,199	\$ 7,745	\$ (57,336)	\$ 9,590	\$ 3,227	\$ 5,818
EBITDA (ex. Impairment Charges)	\$ 11,199	\$ 7,745	\$ 10,256	\$ 9,590	\$ 3,227	\$ 5,818
Adjusted EBITDA	NA	NA	\$ 10,256	\$ 13,126	\$ 6,989	\$ 7,016

Revenue Diversity


2009 Revenues




- Rentals - Colorectal Cancer
- Rentals - Other Cancers
- Rentals - Infectious Disease
- Rentals - Pain Management
- Rentals - Hospitals/Home Care
- Rentals - Service & Repair
- Sales - DP

Revenue Diversity

2009 Revenues



2012 Revenues



- Rentals - Colorectal Cancer
- Rentals - Other Cancers
- Rentals - Infectious Disease
- Rentals - Pain Management
- Rentals - Hospitals/Home Care
- Rentals - Service & Repair
- Sales - DP

Summary Balance Sheet

(\$000's)	12/31/09	12/31/10	12/31/11	12/31/12	3/31/13	6/30/13
ASSETS						
Current Assets:						
Cash and cash equivalents	\$ 7,750	\$ 5,014	\$ 799	\$ 2,326	\$ 472	\$ 102
Account receivable - total, net of allowance	\$ 5,517	\$ 6,679	\$ 7,448	\$ 8,511	\$ 9,570	\$ 9,440
Inventory	\$ 925	\$ 1,699	\$ 1,309	\$ 1,339	\$ 1,378	\$ 1,379
Prepaid expenses and other current assets	\$ 395	\$ 750	\$ 934	\$ 684	\$ 832	\$ 713
Deferred income taxes	\$ 125	\$ 1,147	\$ 682	\$ 1,971	\$ 1,986	\$ 1,986
Total Current Assets	\$ 14,712	\$ 15,289	\$ 11,172	\$ 14,831	\$ 14,238	\$ 13,620
Total PP&E and Medical Equipment	\$ 13,499	\$ 16,672	\$ 17,672	\$ 16,564	\$ 16,653	\$ 17,958
Deferred debt issuance costs, net	\$ 781	\$ 658	\$ 421	\$ 2,362	\$ 2,232	\$ 2,106
Total Goodwill and Intangible assets, net	\$ 85,491	\$ 97,344	\$ 28,221	\$ 25,541	\$ 24,871	\$ 24,221
Deferred income taxes			\$ 18,187	\$ 17,806	\$ 17,755	\$ 17,689
Other assets	\$ 207	\$ 401	\$ 590	\$ 419	\$ 477	\$ 157
Total Assets	\$ 114,690	\$ 130,364	\$ 76,263	\$ 77,523	\$ 76,226	\$ 75,751
LIABILITIES AND STOCKHOLDERS' EQUITY						
Current Liabilities:						
Account payable - total	\$ 1,306	\$ 2,016	\$ 4,063	\$ 2,144	\$ 3,056	\$ 3,833
Accrued expenses and other	\$ 1,573	\$ 4,631	\$ 2,235	\$ 4,098	\$ 4,182	\$ 2,782
Derivative liabilities	\$ 2,670	\$ 183	\$ 258	\$ -	\$ -	\$ -
Current portion of long-term debt	\$ 5,501	\$ 5,551	\$ 6,576	\$ 3,953	\$ 3,872	\$ 3,124
Total Current Liabilities	\$ 11,050	\$ 12,381	\$ 13,132	\$ 10,195	\$ 11,110	\$ 9,739
Long Term Debt, net of current portion	\$ 18,640	\$ 26,646	\$ 22,551	\$ 27,315	\$ 24,594	\$ 25,204
Deferred income taxes	\$ 3,314	\$ 5,788				
Other Liabilities	\$ 221	\$ 406	\$ 415	\$ -	\$ -	\$ -
Total Liabilities	\$ 33,225	\$ 45,221	\$ 36,098	\$ 37,510	\$ 35,704	\$ 34,943
Total Stockholders' Equity	\$ 81,465	\$ 85,143	\$ 40,165	\$ 40,013	\$ 40,522	\$ 40,808
Total Liabilities and Equity	\$ 114,690	\$ 130,364	\$ 76,263	\$ 77,523	\$ 76,226	\$ 75,751
Total Debt	\$ 24,141	\$ 32,197	\$ 29,127	\$ 31,268	\$ 28,466	\$ 28,328

Cash Flow

(\$000's)	FY2009	FY2010	FY2011	FY2012	6 Mo 2012	6 Mo 2013
OPERATING ACTIVITIES						
Net Income	\$ 774	\$ (1,852)	\$ (45,443)	\$ (1,489)		
Adjustments:						
Provision for doubtful accounts	\$ 4,006	\$ 4,515	\$ 4,099	\$ 5,251		
Depreciation	\$ 4,122	\$ 5,357	\$ 6,386	\$ 5,668		
Loss on disposal of pumps	\$ 342	\$ 994	\$ 1,731	\$ 237		
Amortization of intangible assets	\$ 1,827	\$ 2,259	\$ 2,662	\$ 2,734		
Asset impairment charges			\$ 67,592	\$ -		
Stock-based compensation	\$ 753	\$ 3,860	\$ 1,185	\$ 964		
Total Other Adjustments	\$ 2,827	\$ (1,581)	\$ (26,021)	\$ (1,971)		
Changes in assets and liabilities (ex. acquisitions)	\$ (4,943)	\$ (2,740)	\$ (5,445)	\$ (5,942)		
NET CASH PROVIDED BY OPERATING ACTIVITIES	\$ 9,708	\$ 10,812	\$ 6,746	\$ 5,452	\$ 2,274	\$ 2,233
INVESTING ACTIVITIES						
Total Purchases of PP&E, Med. Eq., and Other Assets, net	\$ (4,611)	\$ (2,444)	\$ (4,502)	\$ (2,558)	\$ (419)	\$ (838)
Acquisition of intangible assets			\$ (625)	\$ -		
Cash paid for acquisition, net of cash acquired	\$ -	\$ (16,616)				
NET CASH PROVIDED BY INVESTING ACTIVITIES	\$ (4,611)	\$ (19,060)	\$ (5,127)	\$ (2,558)	\$ (419)	\$ (838)
FINANCING ACTIVITIES						
Net Borrowing on term loan, revolver, and capital leases	\$ (8,565)	\$ 7,377	\$ (5,369)	\$ 1,619	\$ (1,818)	\$ (3,578)
Capitalized debt issuance costs	\$ -	\$ (808)	\$ -	\$ (2,842)		
Common stock withholding on stock based compensation	\$ (135)	\$ (167)	\$ (102)	\$ (144)	\$ (32)	\$ (41)
Treasury shares repurchased	\$ -	\$ (68)	\$ (363)	\$ -	\$ -	\$ -
Principal payments on capital lease obligations	\$ (160)	\$ (822)				
NET CASH PROVIDED BY FINANCING ACTIVITIES	\$ (8,860)	\$ 5,512	\$ (5,834)	\$ (1,367)	\$ (1,850)	\$ (3,619)
Net change in cash and cash equivalents	\$ (3,763)	\$ (2,736)	\$ (4,215)	\$ 1,527	\$ 5	\$ (2,224)
Cash and cash equivalents, beginning of period	\$ 11,513	\$ 7,750	\$ 5,014	\$ 799	\$ 799	\$ 2,326
Cash and cash equivalents, end of period	\$ 7,750	\$ 5,014	\$ 799	\$ 2,326	\$ 804	\$ 102
Free Cash Flow (EBITDA less CapEx & Purchases of ME)	\$ 6,588	\$ 5,301	\$ 5,754	\$ 7,032	\$ 2,808	\$ 4,980
Free Cash Flow (Adj. EBITDA less CapEx & Purchases of ME)			\$ 5,754	\$ 10,568	\$ 6,570	\$ 6,178
Revenue Growth (%)		21.2 %	15.7 %	7.7 %		3.3 %

Take Away



Positioned For Growth

Market Trends

- InfuSystem is uniquely positioned to take advantage of market trends

Strategy

- Transformational strategy is developed and being implemented

Leadership

- Leadership can now focus on running a business for first time in over a year



Thank You for Your Interest!

IR Contact Info:

The Dilenschneider Group

212-922-0900

Rob Swadosh, rswadosh@dgi-nyc.com

Patrick Malone, pmalone@dgi-nyc.com



Appendix: INFU Overview




Third-Party Payor Business Overview

With a national footprint and at four times the size of its largest competitor, InfuSystem is the leading provider of ambulatory infusion pumps to oncologists and their patients

- InfuSystem provides ambulatory infusion pumps and related supplies to outpatient oncology providers, including oncology clinics and hospitals free of charge
- InfuSystem bills the patients' health insurance providers or patients directly
- Pumps are used for the continuous infusion of chemotherapy drugs to treat colorectal and other types of cancer
- The Company offers a complete solution that benefits providers, patients and payors



Leading National Platform



A Complete One-Stop Solution

- Ability to provide any pump, plus related supplies at no cost to clinics
- Billing and collections directly from payors
- Maintain, clean and services equipment in-house
- 24/7 nurse-staffed patient support hotline
- Exceptional ease-of-use through iPad-based billing solutions and connectivity to major Electronic Medical Records (EMR) systems

InfuSystem
INFUSION MADE EASY.™

Key Competitive Advantages

- “In-network” in over 250+ health plans covering approx. 222mm lives
- National footprint with over 1,600+ active healthcare facilities
- 20+ years in Durable Medical Equipment (“DME”) billing and licensing
- Full-service billing capabilities: paper, fax, electronic medical record, iPad
- Regulatory compliance in constantly changing landscape
- 24/7 support line staffed by certified oncology nurses
- Relationships with equipment manufacturers
- In-house refurbishment and repair capabilities
- Premier industry reputation for customer service
- Expansive and diverse fleet includes virtually all makes and models




Payor & Customer Mix

InfuSystem has strong relationships with the largest third-party payors and the leading cancer institutions

- High diversification of providers and payors
 - No single healthcare provider represents more than 7% of Third-Party Payor revenues
 - Strong payor mix among Medicare, other commercial insurers, Blue Cross/Blue Shield, and Medicaid
 - Less than 5% of revenues received directly from patients through co-pays or otherwise
- Broad coverage further diversifies revenue streams

Revenue by Payor (FY2012)



CMS: Centers for Medicare and Medicaid Services

Leading Cancer Institution Customers


9 of 10 of the Top Ten Cancer Treatment Centers



Competitive Landscape

- InfuSystem measures its market share not in terms of the number of practices, but the pool of addressable patients
- The breakdown of the Company's current market share shows that despite being the predominant national player in continuous infusion, there is ample room for organic growth
- The Company competes for market share in all but the Captive Health Plans which represent health plans in which *all* services are rendered by one common payor/provider (e.g., Kaiser Permanente)

Market Share for Oncology Continuous Infusion



Source: American Cancer Society, CMS, National Comprehensive Cancer Network, National Home Infusion Association

InfuSystem
INFUSION MADE EASY.™

Direct Payor Business Model

- InfuSystem's Direct Payor business is focused primarily on the sale, rental, financing and accompanying service of movable medical equipment to hospitals and alternate care sites who pay InfuSystem directly – no third-party reimbursement
- Founded in 1998 and headquartered in Olathe, KS with distribution/service centers in Santa Fe Springs, CA and Mississauga, Ontario
- InfuSystem services – ISO 9001 - and repairs movable medical equipment
- Leading provider to alternate site healthcare facilities and hospitals in the United States and Canada
 - Home infusion providers, long-term care, physician clinics, research facilities, etc.
- Transacts directly with healthcare providers – no third-party reimbursement revenue

Products



InfuSystem sells, rents and finances a wide variety of new and used large volume and ambulatory pumps

- Infusion pumps
- Syringe pumps
- Enteral pumps
- Ambulatory pumps

Service & Repair




InfuSystem services and repairs both its own fleet of pumps and many types of other movable medical

- Large volume pumps
- Fluid collection
- Ambulatory pumps
- Medical equipment



Compelling Value Proposition

Complementary core competencies allow InfuSystem to offer superior selection, flexibility, pricing and services



Direct Payor Offerings

Leading Provider of New and Pre-Owned Pumps

- InfuSystem offers new pumps from top brands
 - Broker-dealer trading desk
 - Web Portal
- In addition, over 70 models and versions of pre-owned pumps are offered
 - Pre-owned pumps are re-built and certified by in-house biomedical technicians to be patient ready
 - Warranty offered on pre-owned pumps
- A variety of financing options to fit customers' operating, budgeting and financing parameters
- Nationwide, industry-leading ISO 9001 service programs
- Launching branch service center in Houston

Pre-Owned & New Pumps from Top Manufacturers



Full Spectrum of Ownership Options for Customers

Rental	Sales	Asset Management
<ul style="list-style-type: none"> ■ Renting new or pre-owned equipment ■ Rent pumps by the day, week or month to match swings in patient count ■ Free shipping on all rentals 	<ul style="list-style-type: none"> ■ Industry leader in sales of pre-owned equipment, creating significant savings ■ Competitive pricing on new equipment ■ Option to sell back pre-owned pumps ■ Leasing plans offered 	<ul style="list-style-type: none"> ■ ISO 9001 Service offered ■ Service plans offered ■ Local service expansion <ul style="list-style-type: none"> ● 2 existing; 1 planned ● Coordinate with TPP ■ Loaner pumps available

Medical Equipment Service & Repair

- In addition to supporting and repairing InfuSystem's in-house fleet, the Company certifies, recalibrates, repairs and services a variety of infusion pumps
- Pumps require scheduled maintenance and calibration in accordance with manufacturer's specifications and regulatory guidelines
- Service and repair capabilities on high demand services reaching end of life that are no longer supported by manufacturers
- ISO certification and an established quality system strengthens relationships with major customers
- Provides InfuSystem an opportunity to establish a business relationship with customers that acquired pumps through other sources
- Continuing and increased need for compliance with current as well as anticipated regulations



- 28 highly qualified service technicians
- 5 major manufacturer relationships:
 - B|BRAUN** SHARING EXPERTISE
 - CME**America.
 - smiths medical
 - MOOG**  Walkmed Infusion
- 3 service centers, located in California, Toronto and Kansas

InfuSystem
INFUSION MADE EASY.™